The process includes gene synthesis, vector construction, plasmid preparation, and transient transfection or stable cell line development. This workflow produces IgM in pentameric or hexameric forms with appropriate disulfide bonding and J-chain formation, ensuring structural integrity and functional efficacy. We also provide traditional hybridoma technology options, including human-human and hetero-hybridomas, for reliable IgM production.